Bristol Myers Squibb Company $BMY Shares Sold by UMB Bank n.a.

Key Points

• UMB Bank n.a. has reduced its holdings in Bristol Myers Squibb Company by 37.4%, selling 117,309 shares, and now owns 196,124 shares valued at approximately $9.08 million.
• The company recently reported a quarterly earnings per share (EPS) of $1.46, exceeding analysts’ expectations, and its revenue for the quarter was $12.27 billion, reflecting a .6% year-over-year increase.
• Bristol Myers Squibb declared a quarterly dividend of $0.62 per share, equating to an annualized yield of 5.5%, with a dividend payout ratio of 100%.

UMB Bank n.a. lessened its position in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 37.4% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 196,124 shares of the biopharmaceutical company's stock after selling 117,309 shares during the period. UMB Bank n.a.'s holdings in Bristol Myers Squibb were worth $9,079,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of BMY. Wright Investors Service Inc. lifted its position in Bristol Myers Squibb by 0.5% during the 2nd quarter. Wright Investors Service Inc. now owns 89,819 shares of the biopharmaceutical company's stock worth $4,158,000 after acquiring an additional 407 shares during the period. Diversified Trust Co raised its position in Bristol Myers Squibb by 16.4% during the second quarter. Diversified Trust Co now owns 64,763 shares of the biopharmaceutical company's stock worth $2,998,000 after acquiring an additional 9,105 shares during the last quarter. Kingstone Capital Partners Texas LLC acquired a new position in shares of Bristol Myers Squibb during the 2nd quarter worth approximately $98,898,000. IFM Investors Pty Ltd raised its holdings in shares of Bristol Myers Squibb by 3.7% in the second quarter. IFM Investors Pty Ltd now owns 413,438 shares of the biopharmaceutical company's stock worth $19,138,000 after acquiring an additional 14,918 shares during the last quarter. Finally, Grove Bank & Trust grew its stake in Bristol Myers Squibb by 3.3% in the 2nd quarter. Grove Bank & Trust now owns 19,529 shares of the biopharmaceutical company's stock worth $904,000 after acquiring an additional 619 shares during the period. Institutional investors and hedge funds own 76.41% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the stock. Wall Street Zen downgraded shares of Bristol Myers Squibb from a "strong-buy" rating to a "buy" rating in a research note on Friday, June 6th. Daiwa Capital Markets lowered shares of Bristol Myers Squibb from an "outperform" rating to a "neutral" rating and set a $42.00 target price for the company. in a research note on Tuesday, August 5th. Morgan Stanley reissued a "hold" rating on shares of Bristol Myers Squibb in a report on Thursday, July 31st. Daiwa America downgraded shares of Bristol Myers Squibb from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, August 5th. Finally, Citigroup dropped their price objective on Bristol Myers Squibb from $51.00 to $47.00 and set a "neutral" rating on the stock in a research note on Friday, August 1st. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fifteen have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $56.38.

Bristol Myers Squibb Stock Performance

BMY traded down $0.11 during midday trading on Tuesday, reaching $44.88. The company had a trading volume of 6,759,020 shares, compared to its average volume of 13,014,886. The stock has a market cap of $91.34 billion, a PE ratio of 18.13, a P/E/G ratio of 2.30 and a beta of 0.35. Bristol Myers Squibb Company has a 12-month low of $42.96 and a 12-month high of $63.33. The company has a debt-to-equity ratio of 2.54, a quick ratio of 1.11 and a current ratio of 1.21. The business has a 50-day moving average price of $46.88 and a two-hundred day moving average price of $49.47.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last issued its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported $1.46 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.07 by $0.39. The company had revenue of $12.27 billion for the quarter, compared to the consensus estimate of $11.32 billion. Bristol Myers Squibb had a return on equity of 80.04% and a net margin of 10.58%.The firm's revenue was up .6% compared to the same quarter last year. During the same quarter last year, the business posted $2.07 earnings per share. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS. On average, sell-side analysts expect that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, November 3rd. Investors of record on Friday, October 3rd will be issued a $0.62 dividend. The ex-dividend date is Friday, October 3rd. This represents a $2.48 annualized dividend and a yield of 5.5%. Bristol Myers Squibb's dividend payout ratio (DPR) is currently 100.00%.

Insider Buying and Selling at Bristol Myers Squibb

In other Bristol Myers Squibb news, EVP David V. Elkins sold 56,000 shares of Bristol Myers Squibb stock in a transaction that occurred on Tuesday, September 2nd. The shares were sold at an average price of $47.33, for a total transaction of $2,650,480.00. Following the transaction, the executive vice president owned 167,379 shares of the company's stock, valued at $7,922,048.07. The trade was a 25.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.07% of the stock is owned by corporate insiders.

Bristol Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.